PBLS · Parabilis Medicines Inc. Common Stock
View on chartInsiders & Stakes
| RA CAPITAL MANAGEMENT, L.P. Director | ▲ Buy | Open Market | 26,529,686 Shares held | 7/22/2026 | View profile |
| James E. Flynn 10% Owner | ▼ Sell | Other | 940,352 Shares held | 6/11/2026 | View profile |
| Levy Guy 10% Owner | ▼ Sell | Other | 527,070 Shares held | 6/11/2026 | View profile |
| Alexis Borisy Director | ▼ Sell | Other | 105,414 Shares held | 6/11/2026 | View profile |
| SEBULSKY ALAN | ▲ Buy | Open Market | 30,000 Shares held | 6/15/2026 | View profile |
| FITZGERALD EDWARD M | ▼ Sell | Other | 14,688 Shares held | 6/11/2026 | View profile |
Transaction History
| RA CAPITAL MANAGEMENT, L.P. | ▲ Buy | Open Market | 47,250 | $1.4M | 7/22/2026 |
| RA CAPITAL MANAGEMENT, L.P. | ▲ Buy | Open Market | 21,696 | $607K | 7/21/2026 |
| RA CAPITAL MANAGEMENT, L.P. | ▲ Buy | Open Market | 6,504 | $190K | 7/21/2026 |
| RA CAPITAL MANAGEMENT, L.P. | ▲ Buy | Open Market | 37,723 | $1.1M | 7/21/2026 |
| RA CAPITAL MANAGEMENT, L.P. | ▲ Buy | Open Market | 98,433 | $2.7M | 7/20/2026 |
| RA CAPITAL MANAGEMENT, L.P. | ▲ Buy | Open Market | 32,987 | $914K | 7/20/2026 |
| SEBULSKY ALAN | ▲ Buy | Open Market | 5,000 | $130K | 6/15/2026 |
| SEBULSKY ALAN | ▲ Buy | Open Market | 4,065 | $110K | 6/15/2026 |
| SEBULSKY ALAN | ▲ Buy | Open Market | 8,435 | $233K | 6/12/2026 |
| RA CAPITAL MANAGEMENT, L.P. | ▼ Sell | Other | 6,556,740 | — | 6/11/2026 |
| RA CAPITAL MANAGEMENT, L.P. | ▲ Buy | Open Market | 19,728,353 | $394.6M | 6/11/2026 |
| FITZGERALD EDWARD M | ▼ Sell | Other | 5,539 | — | 6/11/2026 |
| James E. Flynn | ▼ Sell | Other | 407,132 | — | 6/11/2026 |
| RA CAPITAL MANAGEMENT, L.P. | ▼ Sell | Other | 1,187,881 | — | 6/11/2026 |
| RA CAPITAL MANAGEMENT, L.P. | ▲ Buy | Open Market | 1,460,397 | $29.2M | 6/11/2026 |
| FITZGERALD EDWARD M | ▼ Sell | Other | 5,271 | — | 6/11/2026 |
| SEBULSKY ALAN | ▲ Buy | Open Market | 12,500 | $250K | 6/11/2026 |
| Alexis Borisy | ▼ Sell | Other | 105,414 | — | 6/11/2026 |
| James E. Flynn | ▼ Sell | Other | 122,990 | — | 6/11/2026 |
| James E. Flynn | ▼ Sell | Other | 122,990 | — | 6/11/2026 |
| James E. Flynn | ▼ Sell | Other | 149,238 | — | 6/11/2026 |
| FITZGERALD EDWARD M | ▼ Sell | Other | 3,878 | — | 6/11/2026 |
| James E. Flynn | ▼ Sell | Other | 260,992 | — | 6/11/2026 |
| James E. Flynn | ▼ Sell | Other | 407,132 | — | 6/11/2026 |
| James E. Flynn | ▼ Sell | Other | 149,238 | — | 6/11/2026 |
| James E. Flynn | ▼ Sell | Other | 260,992 | — | 6/11/2026 |
| Levy Guy | ▲ Buy | Open Market | 375,000 | $7.5M | 6/11/2026 |
| Levy Guy | ▲ Buy | Open Market | 125,000 | $2.5M | 6/11/2026 |
| Levy Guy | ▼ Sell | Other | 527,070 | $5.0M | 6/11/2026 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Parabilis Medicines starts dose‑ranging cohort of Zolucatetide trial
Parabilis Medicines has begun a dose‑ranging cohort of its Zolucatetide program in patients with familial adenomatous polyposis, extending its Phase 1/2 clinical study. The new cohort will provide additional safety and efficacy data to help define the optimal dose for this indication. This development comes as the stock trades near a well‑tested support level and analysts maintain a target price near the top of its 52‑week range.
Parabilis Medicines starts dose‑ranging cohort of Zolucatetide trial. Parabilis Medicines has begun a dose‑ranging cohort of its Zolucatetide program in patients with familial adenomatous polyposis, extending its Phase 1/2 clinical study. The new cohort will provide additional safety and efficacy data to help define the optimal dose for this indication. This development comes as the stock trades near a well‑tested support level and analysts maintain a target price near the top of its 52‑week range.